Cargando…
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
Autores principales: | Sun, Yuming, Jin, Liping, Dian, Yating, Shen, Minxue, Zeng, Furong, Chen, Xiang, Deng, Guangtong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406960/ https://www.ncbi.nlm.nih.gov/pubmed/37560258 http://dx.doi.org/10.1016/j.eclinm.2023.102110 |
Ejemplares similares
-
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023) -
Godspeed, EClinicalMedicine
Publicado: (2018) -
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023) -
Corrigendum to “Real-world long-term outcomes in individuals at
clinical risk for psychosis: The case for extending duration of care” [EClinicalMedicine
28 (2020) 100,578]
por: Fusar-Poli, Paolo, et al.
Publicado: (2021) -
Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]”
por: Krolewiecki, Alejandro, et al.
Publicado: (2021)